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Introduction
Despite good progress in the management of patients 
with atrial fibrillation (AF), this arrhythmia remains one of 
the most common sustained cardiac rhythm disorders and 
one of the major causes of stroke, heart failure, sudden death, 
and cardiovascular morbidity in the world [1]. In 2010, the 
estimated numbers of men and women with AF worldwide 
were 20.9 million and 12.6 million, respectively, with higher 
incidence and prevalence rates in developed countries [2,3]. 
By 2030, 14–17 million AF patients are anticipated in the Eu-
ropean Union, with 120 000–215 000 newly diagnosed pa-
tients per year [3,4,5].
The age of patients with this disease increases progres-
sively, that currently the average age is between 75 and 85 
years. This arrhythmia is associated with a 5-fold increase in 
the risk of stroke and a 3-fold increase in the incidence of 
heart failure. The increase in AF prevalence can be attributed 
both to better detection of silent AF, alongside increasing age 
and conditions predisposing to AF [1].
In many patients, AF progresses from short, infrequent 
episodes to longer and more frequent attacks. With time, 
many patients will develop permanent AF. In a small propor-
tion of patients, AF will remain paroxysmal over several de-
cades. Based on the presentation, duration, and spontaneous 
termination of AF episodes, five types of AF are traditionally 
distinguished: first diagnosed, paroxysmal, persistent, long-
standing persistent and permanent AF. If patients suffer from 
both paroxysmal and persistent AF episodes, the more fre-
quent type should be used for the diagnosis [1,6].
Patients who are primary diagnosed with AF are in the 
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category called de novo AF. Many patients with AF are often 
asymptomatic and are diagnosed incidentally during a rou-
tine physical examination. If the patient has more episodes of 
AF lasting up to seven days and that stops on its own the cat-
egory changes to paroxysmal AF. If AF lasting longer than 7 
days is then known as persistent AF [7]. In this case to restore 
sinus rhythm it is recommended to perform planned electri-
cal cardioversion. If the electrical cardioversion is ineffective, 
contraindicated or not performed and AF continues year or 
more the patient's AF is then known as permanent [8]. In 
addition to the above four AF categories, which are mainly 
defined by episode timing and termination, the ACC/AHA/
ESC guidelines describe additional AF categories in terms of 
other characteristics of the patient [9].
Lone atrial fibrillation – the absence of clinical signs and 
symptoms or echocardiographic findings of rheumatic valve 
disease, ischemic heart disease, hypertension, pulmonary 
heart, cardiomyopathy thyrotoxicosis or the left atrium en-
largement in patient under 60 years old.
Secondary AF – the occurrence of arrhythmias in certain 
situations or directly in the acute phase of diseases, such as 
during myocardial infarction, acute pericarditis, pulmonary 
embolism, infectious diseases, brain trauma or thoracic sur-
gery [9].
AF is a chaotic atrial depolarization at a rate of 300-600 
beats per minute and ventricular rate may vary depending on 
atrioventricular (AV) conduction. On the electrocardiogram 
(ECG) we have a completely irregular ventricular rhythm 
and fibrillatory waves of small amplitude and different mor-
phology.
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tricular tachyarrhythmia that in different periods of time 
can coexist on the same patient. Sources of rapid electrical 
discharges are automatic foci localized in the left atrium 
near the pulmonary veins or in a variety of other locations 
through both the left or right atrium [10].
AFL is atrial tachyarrhythmia with frequency of 250-350 
beats per minute. AFL foci are often localized in the cavotri-
cuspidian isthmus in the right atrium [10]. The prevalence of 
AFL is less than one tenth of the prevalence of AF. AFL often 
coexists with or precedes AF [1]. In typical, isthmus-depen-
dent flutter, P waves will often show a “saw tooth” morphol-
ogy, especially in the inferior leads (II, III, aVF). The ventric-
ular rate can be variable (usual ratio of atrial to ventricular 
contraction 4:1 to 2:1, in rare cases 1:1) and macro-re-entrant 
tachycardias may be missed in stable 2:1 conduction [11].
Non-pharmacological measures aimed at “healing” AF 
were tested initially in open surgery. Searching for an ap-
proach with a greater chance of success led to the develop-
ment of ablation with radiofrequency (RFA) without the 
need for open surgery, after having determined that, in many 
patients, AF is initiated and / or maintained by extrasystoles 
with the origin in the pulmonary veins. In the form of persis-
tent AF, pulmonary vein isolation is not sufficient to achieve 
acceptable success rates but are often necessary to modify the 
atrial substrate (discrete ablation and / or linear ablation). 
Reintervention by RFA applies in the case of about 9-20% 
of patients. The frequency of major complications related 
to the ablation is less than 5%. Only recently RFA catheter 
technique began to be used extensively in people with AF, 
not being tested in large randomized studies, with the estab-
lishment of remote results. However, several well-conducted 
randomized trials and systematic reviews have shown that 
both in the persistent AF and paroxysmal AF, catheter abla-
tion is superior to antiarrhythmic drug therapy in terms of 
preventing recurrences [12].
According to recent guidelines, prevention of recurrence 
of AF using RFA is warranted in patients with symptomatic 
paroxysmal form, RFA catheter may be considered after fail-
ure of first line antiarrhythmic drugs. Thus, in those without 
structural heart disease, RFA is an alternative to treatment 
by antiarrhythmic drugs if they have been found to be in-
effective. In cases where the medication with amiodarone 
is the first line therapy due to the presence of contraindica-
tions for IC antiarrhythmic class RFA may be considered if 
amiodarone does not work [12]. The guides are equivocal 
regarding persistent AF patients. RFA can be indicated for 
cases of recurrent AF with severe symptoms after the failure 
of an antiarrhythmic drug. Such a recommendation is not 
based on solid evidence, but is supported by small case series 
and randomized trials that show that, in patients with heart 
failure restoring sinus rhythm (SR), the ablation catheter can 
be associated with significant improvement in left ventricular 
ejection fraction [12].
Obesity may increase the rate of AF recurrence after cath-
eter ablation, with obstructive sleep apnea as an important 
potential confounder. Obesity has also been linked to a high-
er radiation dose and complication rate during AF ablation 
[13,14]. Notably, the symptomatic improvement after cath-
eter ablation of AF in obese patients seems comparable to the 
improvement in normal-weight patients. In view of the po-
tential to reduce AF episodes by weight reduction, AF abla-
tion should be indicated to obese patients in association with 
lifestyle modifications that lead to weight reduction [1,15].
Technique of Radiofrequency Ablation
RFA is a minimally invasive procedure, which is per-
formed in the electrophysiological laboratory, usually under 
mild sedation and only in rare cases with general anesthesia. 
Electrophysiology physician will perform femoral vein punc-
ture. Subsequently, under radiological control will be intro-
duced diagnostic and ablation catheters through the femoral 
vein and inferior vena cava up to the heart (in right atrium). 
Then the physician will puncture the interatrial septum to 
penetrate in this way into the left atrium, the place of en-
trance of the four pulmonary veins, where he identifies the 
most common sites of occurrence of AF. Responsible sites 
will be identified by a special technique of cardiac “mapping”. 
The catheter uses radiofrequency energy (RE) to create a le-
sion and to block the pathologic circuit that generates AF. 
This procedure is called pulmonary vein isolation and is the 
most common procedure used in radiofrequency ablation for 
AF [16].
Under the same procedure, the physician can apply radio-
frequency energy to an area of the right atrium, which is the 
cause of other arrhythmias, atrial flutter, commonly found 
in patients with AF. The procedure usually takes a few hours 
[16].
The objective of curative treatment of typical atrial flut-
ter is to discontinue the leadership in cavotricuspid isthmus 
by providing a complete line of ablation, by drawing point 
to point of some types of successive RE and obtaining sinus 
rhythm. The absence of relapses is provided only in case of 
a complete bidirectional block. RFA for typical atrial flutter 
has a high success rate in more than 80% and low risk of re-
lapse. In case of atypical atrial flutter, success of the proce-
dure depends on the location of the circuit, and recurrences 
are more frequent and can even require later antiarrhythmic 
therapy. Also, atypical atrial flutter that is secondary to AF 
ablation may be difficult to treat with RFA [16].
Another procedure of RFA is circumferential ablating of 
left atrium, which consist in making some confluent ablative 
lesions around the orifice of the pulmonary veins entrance, 
usually grouped two by two, these two circles can be joined 
together or with other anatomical structures (e.g.: mitral 
valve ring) with additional ablation lines. These additional 
lines have as a purpose left atrial flutter prevention (which 
may occur especially if the ablation lines are incomplete). 
The optimal ablation procedure varies from patient to patient 
[16].
There is a consensus that administration of oral antico-
agulation (OAC) in peri-procedural ablation is effective in 
preventing thromboembolic complications. This applies both 
to patients who have an indication for long-term OAC and in 
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patients with risk factors for stroke, stressing that somehow 
ablation increases stroke risk in peri-procedural period [17].
According to the recommendations of the 2010 Guide-
lines, OAC long-term therapy post-ablation is recommended 
in patients with a score CHA2DS2-VASc ≥2, regardless of the 
apparent procedural success [17]. Anticoagulation should be 
maintained for at least 8 weeks after ablation for all patients. 
The true incidence of thromboembolic events after catheter 
ablation has never been systematically studied and the ex-
pected stroke risk has been adopted from nonablation AF 
cohorts. Although observational studies suggest a relatively 
low stroke rate in the first few years after catheter ablation of 
AF, the long-term risk of recurrent AF and the safety profile 
of anticoagulation in ablated patients need to be considered. 
In the absence of controlled trial data, OAC after catheter ab-
lation should follow general anticoagulation recommenda-
tions, regardless of the presumed rhythm outcome [1].
It is not uncommon to reappear arrhythmia after abla-
tion in the first 2-4 weeks. It may take 1-3 months for heal-
ing of postablation scars in order to check the success of the 
procedure. In this interval antiarrhythmic therapy may be 
required. Surveillance to detect recurrent AF after RFA is 
important, so it is recommended that the first visit to elec-
trophysiology physician will be 3 months post-ablation, then 
every 6 months during the first two years [12].
Outcome of catheter ablation for atrial fibrillation
After several procedures for catheter ablation of AF was 
observed that better results are obtained in young patients 
with short episodes of AF and in the absence of structural 
heart disease. Sinus rhythm is found in up to 70% of patients 
with paroxysmal AF and in 50% of patients with persistent 
AF. Many patients require more than one ablation procedure 
to obtain rhythm control. RFA reintervention is necessary in 
the approximately 9-20% of patients with more modest re-
sults. It is important that before ablation procedure the pa-
tient to be well informed about the benefits and the risks.The 
decision to continue treatment of AF with antiarrhythmic 
drugs or with RFA always belongs to patient [1].
Complications of catheter ablation for atrial fibrilla-
tion
EURObservational Research Programme (EORP) de-
termined that the average length of hospital stay of patients 
after RFA is 3 days [18,19]. The frequency of major complica-
tions related to RFA is less than 5%-7 % [20]. Intraprocedural 
death has been reported, but is rare (0.2%) [1].
Possible complications post-RFA:
Injury to vessels, nerves, organs and surrounding tis-
sues by manipulating instruments
Renal damage or allergies
Infection or bleeding at injection site
Arterio-venous fistula on puncture site
Complete AV block requiring pacemaker implantation 
(under 1%);
Pericardial effusion, cardiac tamponade
Stroke; pulmonary vein stenosis
Acute coronary syndrome
Atrio-esophageal fistula especially in circumferential 
atrial ablation
Pyloric spasm and gastric hypomotility by affecting the 
vagus nerve during ablation [12, 21].
Conclusions
Catheter ablation is successfully used in patients suffering 
from symptomatic paroxysmal AF, as an alternative to drug 
therapy. Performed correctly by a trained and experienced 
electrophysiolologist, RFA allows us to get remarkable results, 
being possible suspension of treatment with antiarrhyth-
mic drugs such as: amiodarone, dronedarone, flecainide, 
propafenone,sotalol etc. and to avoid its so well known side 
effects. RFA is superior to antiarrhythmic drug therapy in 
preventing recurrence in both persistent AF and in the par-
oxysmal AF. 
All patients should receive oral anticoagulation for at least 
8 weeks after catheter ablation. The success rate of RFA in 
experienced centers for paroxysmal AF exceeds 70% a year. 
RFA reintervention is necessary in the approximately 9-20% 
of patients with more modest results. The frequency of ma-
jor complications related to RFA is less than 5%. The restored 
sinus rhythm with RFA in patients with heart failure may be 
associated with significant improvement in left ventricular 
ejection fraction.
References
1. Paulus Kirchhof, Stefano Benussi, Dipak Kotecha et al. Guidelines for 
the management of atrial fibrillation developed in collaboration with 
EACTS. European Heart Journal 2016; 37: 2893–2962.
2. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin 
EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden 
of Disease 2010 Study. Circulation 2014;129:837–847.
3. Colilla S, Crow A, PetkunW, Singer DE, Simon T, Liu X. Estimates of 
current and future incidence and prevalence of atrial fibrillation in the 
U.S. adult population. Am J Cardiol 2013;112:1142–1147.
4. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, 
Witteman JC, Stricker BH, Heeringa J. Projections on the number of 
individuals with atrial fibrillation in the European Union, from 2000 
to 2060. Eur Heart J 2013;34: 2746–2751.
5. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiol-
ogy of atrial fibrillation: European perspective. Clin Epidemiol 
2014;6:213–220.
6. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, et al. Long-
term progression and outcomes with aging in patients with lone atrial 
fibrillation: a 30-year follow-up study. Circulation 2007;115:3050–3056.
7. Levy S «Classification system of atrial fibrillation» Current Opinion in 
Cardiology. 2000;15 (1): 54–57.
8. Zoni-Berisso, M; Lercari, F; Carazza, T; Domenicucci, S. «Epidemiol-
ogy of atrial fibrillation: European perspective». Clinical epidemiol-
ogy.2014; 6: 213–20.
9. Fuster V, Rydén LE, Cannom DS, «ACC/AHA/ESC 2006 Guidelines 
for the Management of Patients with Atrial Fibrillation” : Circulation. 
2006 Aug 15;114(7): 257-354.
10. Valentin Fuster, Lars E. Rydén, Richard W. et al. ACC/AHA/ESC 
Guidelines for the Management of Patients With Atrial Fibrillation: 
Executive Summary A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and the 
European Society of Cardiology Committee for Practice Guidelines 
and Policy Conferences Circulation. 2001;104:2118-2150.
43
44
REVIEW ARTICLESThe Moldovan Medical Journal, April 2017, Vol. 60, No 2
11. Bun SS, Latcu DG, Marchlinski F, Saoudi N. Atrial flutter: more than 
just one of a kind. Eur Heart J 2015;36:2356–2363.
12. Josephson ME. Catheter and surgical ablation in the therapy of ar-
rhythmias. In: Clinical Cardiac Electrophysiology, 4th, Lippincott, 
Philadelphia 2008; 319–1800.
13. Ector J, Dragusin O, Adriaenssens B, Huybrechts W, Willems R, Ector 
H, Heidbuchel H. Obesity is a major determinant of radiation dose in 
patients undergoing pulmonary vein isolation for atrial fibrillation. J 
Am Coll Cardiol 2007;50:234–242.
14. Shoemaker MB, Muhammad R, Farrell M, Parvez B, et al. Relation 
of morbid obesity and female gender to risk of procedural complica-
tions in patients undergoing atrial fibrillation ablation. Am J Cardiol 
2013;111:368–373.
15. Cha YM, Friedman PA, Asirvatham SJ, Shen WK, Munger TM, Rea RF, 
Brady PA, Jahangir A, Monahan KH, Hodge DO, Meverden RA, Gersh 
BJ, Hammill SC, Packer DL. Catheter ablation for atrial fibrillation in 
patients with obesity. Circulation 2008;117:2583–2590.
16. Chen J, De Chillou C, Basiouny T, Sadoul N, J Da Silva Filho, Magnin-
Poull I, Messier, Aliot E. Cavotricuspid Isthmus Mapping to Assess 
Bidirectional Block During Common Atrial Flutter Radiofrequency 
Ablation. Circulation 1999; 100–2507.
17. A. John Camm, Gregory YH Lip, Raffaele De Caterina et al. Roma-
nian Journal of Cardiology ,,Actualizarea ghidului de management al 
fibrilaţiei atriale al Societăţii Europene de Cardiologie, 2012’’, 2013; 
Vol.23, No.2: 67–88.
18. Kirchhof P, Breithardt G, Bax J, Benninger G, et al. A roadmap to 
improve the quality of atrial fibrillation management: proceedings 
from the fifth Atrial Fibrillation Network/European Heart Rhythm 
Association consensus conference. Europace 2016;18:37–50
19. Cappato R, Calkins H, Chen SA, Davies W, et al. Updated worldwide 
survey on the methods, efficacy, and safety of catheter ablation for 
human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32–38.
20. Dagres N, Hindricks G, Kottkamp H, et al. Complications of atrial 
fibrillation ablation in a high-volume center in 1,000 procedures: still 
cause for concern? J Cardiovasc Electrophysiol 2009;20:1014–1019.
21. Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson 
KC, Brooks AG, Sanders P. Complications of catheter ablation of 
atrial fibrillation: asystematic review. Circ Arrhythm Electrophysiol 
2013;6:1082–1088.
